Cancers (Nov 2021)

Applications of Radiomics and Radiogenomics in High-Grade Gliomas in the Era of Precision Medicine

  • Anahita Fathi Kazerooni,
  • Stephen J. Bagley,
  • Hamed Akbari,
  • Sanjay Saxena,
  • Sina Bagheri,
  • Jun Guo,
  • Sanjeev Chawla,
  • Ali Nabavizadeh,
  • Suyash Mohan,
  • Spyridon Bakas,
  • Christos Davatzikos,
  • MacLean P. Nasrallah

DOI
https://doi.org/10.3390/cancers13235921
Journal volume & issue
Vol. 13, no. 23
p. 5921

Abstract

Read online

Machine learning (ML) integrated with medical imaging has introduced new perspectives in precision diagnostics of high-grade gliomas, through radiomics and radiogenomics. This has raised hopes for characterizing noninvasive and in vivo biomarkers for prediction of patient survival, tumor recurrence, and genomics and therefore encouraging treatments tailored to individualized needs. Characterization of tumor infiltration based on pre-operative multi-parametric magnetic resonance imaging (MP-MRI) scans may allow prediction of the loci of future tumor recurrence and thereby aid in planning the course of treatment for the patients, such as optimizing the extent of resection and the dose and target area of radiation. Imaging signatures of tumor genomics can help in identifying the patients who benefit from certain targeted therapies. Specifying molecular properties of gliomas and prediction of their changes over time and with treatment would allow optimization of treatment. In this article, we provide neuro-oncology, neuropathology, and computational perspectives on the promise of radiomics and radiogenomics for allowing personalized treatments of patients with gliomas and discuss the challenges and limitations of these methods in multi-institutional clinical trials and suggestions to mitigate the issues and the future directions.

Keywords